anthonyyazdaniml/gliner-biomed-balanced-curated-corpus huggingface dataset:
The present invention provides a novel cathartic product for the safe and rapid defecation of anuses, which is composed of three kinds of raw materials, namely sodium chloride, glycerin and water. A defecation effect can be generated within 3 minutes to 7 minutes by the cathartic for anuses of the present invention. Compared with the glycerin cathartic for anuses sold on markets, the patient needs 15 minutes to 1 hour to start defecation, and is shortened greatly. The contents of the glycerin and the sodium chloride in the cathartic of the present invention are respectively 50% to 80% and 0.625% to 2.5%. The concentration of the sodium chloride is lower than the concentration of hypertonic saline solution. The electrolyte balance in a patient&#39;s body can not be disturbed by the concentration of the sodium chloride, and too much mucosa mucus in a patient&#39;s excrement can not be caused either.
The impact on cognitive function, the quality of sleep and the improve mood is a common problem among human due to the nature of work and life. The aim of this study is to investigate the effect of compound essential oil on human by using sniffing. Furthermore, to observe if the blended essential oil has synergistic effect. The objects are divided into control group and experimental groups of Compound essential oil collocating sniffing. Compound essential oil after sniffing, we measured the objects&#39; physiological parameters and HRV parameters. In the future, this intervention may be applied in activities of daily living and outpatient departments to promote the health of human.
PCT No. PCT/JP92/01642 Sec. 371 Date Jun. 17, 1994 Sec. 102(e) Date Jun. 17, 1994 PCT Filed Dec. 17, 1992 PCT Pub. No. WO93/12798 PCT Pub. Date Jul. 8, 1993.The present invention provides a method for using the anti-obesity agent comprising 4-cholesten-3-one represented by the following formula:   &lt;IMAGE&gt;   as an effective component. The anti-obesity agent of the present invention is useful because of inhibition effect of body weight increase and body fat accumulation. The present invention also provides a medicinal composition comprising 4-cholesten-3-one as an effective component and a pharmaceutically acceptable excipient as well as methods for preventing and treating obesity comprising administering an effective amount of 4-cholesten-3-one to a person.
PURPOSE:To obtain a skin drug for external use, by blending Cuscuta seed with an antimicrobial agent or keratinous peeling agent, excellently permeable into the skin without giving irritation or hormonal side effect and particularly effective in preventing, curing and treating pimples and preventing dandruff by applying to the scalp. CONSTITUTION:A skin drug for external use obtained by blending powdered Cuscuta seed which is a crude drug or an extracted essence prepared by extracting the powdered Cuscuta seed with water or an aqueous alcohol, e.g., ethanol, at 15-25 deg.C with sulfur, hinokitiol, photosensitive element No.201, antimicrobial agent, e.g. thioxolone, etc., and/or keratinous peeling agent, e.g. salicylic acid, resorcin, etc. The amount of the blended powdered Cuscuta seed or essence thereof (residue obtained by distilling away the extracting solvent) is &gt;=0.005wt% in the total composition. The amount of the blended antimicrobial agent is 0.001-10wt% and the amount of the blended keratinous peeling agent is 0.01-20wt%. Furthermore, other adjuvants may be blended. The above- mentioned drug is used in the form, e.g. cream, ointment, lotion, tonic, etc., applicable to the integument.
The Access and Temperature Monitoring system (ATMs) checks the identity and health of persons seeking access to a facility, building, event, airport border, or controlled area. It quickly checks the person&#39;s identity by recognizing the person, for example, by facial recognition, or by reading a unique token the person has, such as a smart card. If the person seeking access is recognized, the system quickly checks the health of the person. For example, a contactless measuring of core temperature is taken and is then compared to an on-file core temperature of the individual to see if it is elevated. If elevated, a secondary check is made by a precision medical instrument and compared to the precision data on file. Networking ATMs together to an Access Control Center will further assist in identifying virus outbreaks and reduce response time to assist in saving lives.
The present disclosure belongs to the field of health care products, disclosing a powder made from xylo-oligosaccharide, isomaltooligosaccharide, mannitol, synanthrin, Codonopsis Radix, Hericium erinaceus polysaccharide, Dioscoreae Rhizoma, Poria, Semen Dolichoris Album, Citri Reticulatae Pericarpium, Amomi Fructus and Atractylodis Macrocephalae Rhizoma. The raw materials of the powder are all from natural Chinese herbal medicine without addition of excipient. It is clean and has natural components, in line with people&#39;s pursuit of natural and health foods. In addition, dosage required for the powder is small; it can be taken orally or dissolved in water; it is soluble in cold water and melts in mouth; it has a good taste and can be absorbed quickly. The method for preparing the powder in the present disclosure is simple and suitable for large-scale production. Also, it is easy to be carried. The powder obtained has a good stability and long storage time. Experiments show that the powder of the present disclosure can improve gastric mucosal injury, effectively reduce the acute gastric mucosal injury caused by ethanol, and has a good regulatory effect on intestinal flora, therefore can be used to prepare the health care foods having functions on regulating gastrointestinal tract and protecting gastric mucosa.
1,253,500. Contraceptive method. SCHERING A.G. 19 April, 1968 [19 April, 1967], No. 1714/71. Divided out of 1,231,412. Heading A5B. A method of contraception comprises the administration to a human female, parenterally or by implantation, of a gestagen free from oestrogens in a dose as hereinafter defined in any single menstrual cycle. The gestagen dosage is defined as that having an effect on the cervical mucus which corresponds to that produced by 1 to 20 mg. of 19-nor-17α-hydroxy progesterone caproate when administered in the same way. The term &#34;gestagen&#34; refers to progestational hormones (progestogens or progestins) having a pituitary hypothalamic inhibiting action or which have such action only at a dose above the minimum dose which produces gestagenic action. Typical compounds are: progesterone; its 3-enol esters and 17α-hydroxy-deviations, the 17-esters of 6α- methyl-17α-hydroxy progesterone and 17α- ethynyl-18-homo-19-nor-testosterone and its esters.
Systems, methods, and computer-readable media for providing clinical information to clinicians are provided. In embodiments, a patient&#39;s electronic health record is accessed to identify that a first clinician has requested a consult with a second clinician. Each clinician is associated with a clinician identifier that is identified by a plurality of sensors. A location for both the first and second clinician is received from the plurality of sensors. A determination is made whether the first and second clinicians are near one another. Upon determining that the first and second clinicians are near one another, a notification is presented to the first clinician. Such tracking of clinician location helps avoid missed opportunities and provides efficient communication among clinicians.
PROBLEM TO BE SOLVED: To obtain the subject novel substance that has excellent anti-tumor action and is useful as a therapeutic agent for cancer. SOLUTION: This compound is represented by the formula and has the following physical and chemical properties: description; yellow amorphous solid or crystals; the molecular formula: C22 H9 N2 O4 Cl5 ; mass spectrometry: [high- resolution FAB-MS] the observed value of 540.9055, the calculated value of 540.9085 as (M+H)&lt;+&gt; ; solubility: readily soluble in organic solvents as dimethyl sulfoxide, slightly soluble in water; distinction of acidic, neutral and basic: almost neutral. This compound is obtained by culturing a microorganism that is capable of producing the compound of the formula such as Streptomyces sp. A 55051 (FERM P-16028) and collecting the compound from the cell bodies. In a preferred embodiment, this microorganism is cultured aerobically by the shaking culture or by aerobic submerged culture.  The culture medium is kept at a pH of 4-8, the temperature of 12-39 deg.C for 120-216 hours.
1333826 Hydrorefining oils ESSO RESEARCH &amp; ENG CO 11 Jan 1971 [16 Feb 1970] 1296/71 Heading C5E A colourless and odourless oil for cosmetics is made by refining a heavy alkylate bottoms oil, having a boiling range between 540‹ and 800‹ F., a viscosity at 100‹ F. between 75 SSU and 3000 SSU and a viscosity index between 0 and - 200, in a hydrogen-refining zone in the presence of a sulphur-insensitive catalyst at 400-700‹ F., a hydrogen pressure of 150- 2000 p.s.i.g., a liquid hourly space velocity of 0À1-20 and 100-1000 s.c.f. of hydrogen per barrel and then hydrogenating the hydrogen refined oil in the presence of a Group VIII metal catalyst at 300-650‹ F., a hydrogen pressure of 300-3000 p.s.i.g., a liquid hourly space velocity of 0À1-3 and 300-2500 s.c.f. of hydrogen per barrel. Suitable hydrogen-refining catalysts are molybdenum disulphide, molybdenum oxide or cobalt molybdate on alumina. Suitable hydrogenation catalysts are platinum, palladium, rhodium or nickel on kieselguhr. A heavy alkylate bottoms oil by-product of the sulphuric acid catalysed isobutane or isopentane alkylation of C 3  to C 5  olefins is distilled at 12 and 16 to provide a stream 19 which is refined at 20 and then hydrogenated at 24. The stream 19 can be a single boiling-range fraction or a blend of several such fractions.
&lt;P&gt;PROBLEM TO BE SOLVED: To obtain an excellent mangosteen-processed material having a weak adverse effect and to provide a method for producing the same.  &lt;P&gt;SOLUTION: The mangosteen-processed material having an improved xanthone absorption comprises ground mangosteen and has an improved xanthone absorption. The method for producing the mangosteen-processed material comprises a process of adding an apple juice and a lipase for transesterification to the ground mangosteen and heating the mixture. The method for producing the mangosteen-processed material comprises grinding mangosteen and adding an apple juice and a lipase for transesterification to the ground mangosteen so as to increase an xanthone absorption from the intestinal tract by the lipase. The method for producing the mangosteen-processed material comprises a process of adding ground soybean and Bacillus natto to ground mangosteen and fermenting the mixture. The method for producing the mangosteen-processed material having an improved xanthone absorption comprises a process of fermenting ground mangosteen and ground soybean with Bacillus natto. The mangosteen-processed material is used as a food preparation, a pharmaceutical preparation and a cosmetic.  &lt;P&gt;COPYRIGHT: (C)2009,JPO&amp;INPIT
NEW MATERIAL:The compound of formula (R&lt;1&gt;CO is 8-22C straight-chain acyl; R&lt;2&gt; is 12-22C straight-chain or branched alkyl) and its acid addition salt. EXAMPLE:N&lt;alpha&gt;-lauroyl-arginine stearyl ester hydrochloride. USE:A hair cosmetic. It has excellent softening effect, antistatic effect and smoothening effect to hair, given little irritation to the eye and scalp and has high storage stability. PREPARATION:The objective compound of formula can be produced by condensing a 8-22C halogenated acyl compound with arginyl in the presence of a base and esterifying the product with a 12-22C primary, secondary or tertiary alcohol in the presence of an acid catalyst. The acid catalyst is e.g., HCl, H2SO4 and AlCl3.
PROBLEM TO BE SOLVED: To obtain an agent comprising a hydroxystilbene and capable of stimulating skin desquamation and regeneration without causing unpleasant piquant pain, stretching cramping feeling, flush and redness. SOLUTION: This agent comprises at least one kind of hydroxystilbene (preferably, 3,4&#39;,5-trihydroxystilbene or the like) preferably in an amount of 0.001-10% of the total weight, and is useful for stimulating skin desquamation and/or regeneration, and/or resisting endogenous and/or exogenous skin aging. The agent is used preferably in a shape of emulsion, aqueous solution which is optionally gelatinized, lotion such as two layer lotion, cream, milk or foam. The agent optionally contains an oil phase comprising an animal, plant, mineral, silicone, fluorinated and/or synthetic oil as a base. The oil phase further optionally contains a makeup-removing oil (e.g. an fatty acid ester).
The present invention relates to allergy field. Several independent groups have recently investigated the implication of PCSK9 on inflammation and sepsis but none of them have determine its impact on allergies and/or asthma which is a global health burden. Inventors have obtained preliminary data on wild-type (PCSK9+/+) or PCSK9-deficient mice (PCSK9 −/−) and shown that, under basal condition and in the absence of a particular stimulus, PCSK9 deficiency significantly increases the percentage of regulatory T cells in the spleen, the mesenteric lymph nodes and Peyer&#39;s patches. Moreover, inventors have shown the effect of allergic challenge Non primary human bronchial epithelial cells on PCSK9 expression and secretion. Very interestingly, their first results obtained by Q-PCR showed that HDM and LPS increase PCSK9 mRNA levels. Accordingly, the present invention relates to inhibitors of PCSK9 for use in the treatment of asthma and/or allergic disease, such as food allergy.
&lt;P&gt;PROBLEM TO BE SOLVED: To develop a new compound having high antioxidizing actions and to make application to an antioxidant, a cosmetic composition and a food composition by using the compound.  &lt;P&gt;SOLUTION: The antioxidant comprises a compound represented by formula (1) or its pharmaceutically acceptable salt as an active ingredient. The new compound represented by formula (1) has excellent antioxidizing actions, for further detail, active oxygen scavenging actions. The antioxidant having a high antioxidizing ability can be composed by using the new compound. Furthermore, effective prophylaxis of various disorders or diseases caused by the active oxygen or effective antioxidation of products themselves of the cosmetic composition or food composition can be expected by using the antioxidant in the cosmetic composition or food composition.  &lt;P&gt;COPYRIGHT: (C)2005,JPO&amp;NCIPI
NEW MATERIAL:The compound of formula I (R1-R3 are H, OH or &lt;=5C alkoxy or two of R1-R3 together form the group of formula IV or formula V; n is 0- 4; the dotted line represents single or double bond) or its salt. EXAMPLE:6-{4-[4-( 2, 3, 4-Trimethoxybenzyl )-1-piperazinylcarbonyl]phenyl}-4, 5- dihydro-3(2H)-pyridazinone. USE:A cardiotonic having high activity and exhibiting the activity sufficiently for a long period. The salt of the compound has also vasodilating effect. PREPARATION:The compound of formula I can be prepared by reacting the carboxylic acid of formula II with an alkylhalocarboxylic acid to obtain a mixed acid anhydride, and carrying out the conventional amide-bond formation reaction by reacting the anhydride with an amine of formula III in a mixture of dimethylamide and tetrahydrofuran, etc. in the presence of a basic compound such as triethylamine.
Composition comprises at least one chlorite and a polyvalent alcohol in aqueous or alcoholic-aqueous chlorine dioxide-containing solution without other chlorine oxide compounds, chlorates and oxidants, preferably peroxides. The composition has a pH value of &gt;= 4. Independent claims are also included for: (1) a solid material composition for preparing the composition by dissolving the solid material composition in water and/or alcohol; and (2) an agent for internal or external application for therapeutic, prophylactic, cosmetic or health-promoting functions in humans and animals, comprising the composition or the solid material composition. ACTIVITY : Antibacterial. No biological data given. MECHANISM OF ACTION : None given.
The present invention relates to mammalian hematopoietic facilitatory cells (FC). In particular, it relates to the isolation, characterization and uses of the FC. The FC of the present invention can be distinguished from all other known bone marrow cells by their morphology, cell surface phenotype and in vivo function. It has now been established that purified hematopoietic stem cells alone or bone marrow cells depleted of FC do not readily engraft in a recipient. When co-administered with other bone marrow cells, especially the hematopoietic stem cells into a recipient, the FC  enhance their engraftment, without apparent adverse biologic activities. In fact, the ability of the FC to enhance the engraftment of bone marrow cells in establishing lymphohematopoietic chimerism without producing graft versus host disease also induces donor-specific tolerance to permit the permanent acceptance of donor&#39;s cells, tissues and organs. Therefore, FC may have a wide range of applications, including, but not limited to, hematopoietic reconstitution by bone marrow transplantation for the treatment of cancers, anemias, autoimmunity, immunodeficiency, viral infections and metabolic disorders as well as facilitation of solid organ, tissue and cellular transplantation.
&lt;P&gt;PROBLEM TO BE SOLVED: To provide composition for oral use which effectively exerts a bactericidal action of a cationic bactericide within the oral cavity, is extremely effective for preventing and improving tooth decay, peridontal diseases, stench, or the like, and exerts an excellent shelf stability at low temperatures.  &lt;P&gt;SOLUTION: This composition for oral use is a sol-gel transition preparation containing a cationic bactericide and a temperature-sensitive polyoxyethylene/ polyoxypropylene block copolymer surfactant. Here, the polyoxyethylene/ polyoxypropylene block copolymer surfactant is a combined system of (A) a surfactant wherein the polyoxyethylene portion accounts for 75-85% of the total molecular weight and the polyoxypropylene portion has a molecular weight of 2,000-2,500 and (B) a surfactant wherein the polyoxyethylene portion accounts for 65-75% of the total molecular weight and the polyoxypropylene portion has a molecular weight of 3,400-4,300. The compounding ratio of (B) to (A) is 2-30%, and the total amount of surfactants (A) and (B) accounts for 10-25 wt.% of the composition for oral use. The sol-gel transition temperature is within the range of 20-45°C.  &lt;P&gt;COPYRIGHT: (C)2003,JPO
It is found out that m-calpain or .mu.-calpain degrades hepatocyte nuclear factor 4.alpha. (HNF-4.alpha.), hepatocyte nuclear factor 1.alpha. (HNF- 1.alpha.) and insulin promoter facotr 1 (IPF-1) which form a transcriptional factor network participating in the expression of a saccharomyces-associated gene in pancreatic .beta.-cells. Thus, a method of degrading these transcriptional factors; a method of inhibiting the degradation; a degradati on inhibitor; a promoter for the production of a gene product of a gene on whic h these factors serve as transcriptional factors and a method of promoting the production; a preventive and/or a remedy for a disease caused by the degradation of these transcriptional factors and a method of preventing and/ or treating the same; a method of identifying a compound inhibiting the degradation of these transcriptional factors by calpain; a compound obtained by the identification method; and a reagent kit containing calpain, these transcriptional factors, polynucleotides encoding these transcriptional factors, and a vector containing these polynucleotides; are provided.&lt;/SDOAB &gt;
1378671 Cleaners containing bleach PROCTER &amp; GAMBLE CO 21 Feb 1972 [22 Feb 1971] 7963/72 Heading C5D [Also in Division D1] A chlorine-free, dry bleach composition which may be used for cleaning sinks, dentures and textiles comprises: (A) from 8 to 60% by weight of a bleaching agent selected from: (i) sodium monopersulphate, (ii) potassium monopersulphate, (iii) an organic peroxyacid or water-soluble salt thereof, said peroxyacid having the general formula wherein R is a substituted (e.g. by Cl), unsubstituted alkylene, or arylene group and Y is a group providing an anionic moiety in aqueous solution, e.g. -COO-, SO 3  or -CO.OO-, and (iv) mixtures thereof; (B) from 10 to 60% by weight of a quaternary ammonium compound of the general formula  wherein R 1  is an alkyl group containing from 12 to 20 carbon atoms; R 2  is selected from alkyl groups containing from 1 to 14 carbon atoms, cycloalkyl groups containing from 5 to 8 carbon atoms, carboxymethyl groups, aryl groups containing from 6 to 8 carbon atoms, alkaryl groups containing from 7 to 10 carbon atoms, pyridyl, and groups of the general formula -(C 3 H 6 O) a (C 2 H 4 O) b H, wherein a and b are 0 or integers and a+b is from 1 to 50; R 3 , R 4  and R 5  are each selected from alkyl groups containing from 1 to 3 carbon atoms, aryl groups containing from 6 to 8 carbon atoms, cycloalkyl groups containing from 5 to 8 carbon atoms, carboxymethyl groups, alkaryl groups containing from 7 to 10 carbon atoms, pyridyl, and groups of the general formula wherein a and b are 0 or integers and a+b is from 1 to 50; R 6  represents one of the groups given for R 3 , R 4  and R 5  or is H; R 7  is an alkylene group containing from 1 to 3 carbon atoms, an arylene group containing from 5 to 8 carbon atoms or a group of the formula wherein X is a non-interfering water-soluble salt forming mono- or divalent anion; and wherein n is 1 when X is a monovalent anion and n is 2 when X is a divalent anion; and (C) from 10 to 75% by weight of a buffering agent effective to maintain a solution pH of from 7 to 10 when said composition is dissolved in water for bleaching, e.g. phosphates, hydrogen phosphates, carbonates or bicarbonates. An aqueous bleaching solution may be formed by dissolving components (A) and (B) in water whilst maintaining the pH between 7 and 10. The aqueous solutions can be used for bleaching and softening cotton fabrics.
PROBLEM TO BE SOLVED: To provide the subject coated sheet, causing no problem when adhering to the skin, e.g. stimulating or roughening the skin, and capable of efficiently supplying a given agent to, and allowing it to act on, the target portion by including a polyolefin-based resin and agent which acts on the skin or hair. SOLUTION: This coated sheet is obtained by including (A) 100 pts.wt. of a polyolefin-based resin and (B) 0.01 to 100 pts.wt. of an agent which acts on the skin or hair. The preferable component A is an α-olefin polymer (e.g. polyethylene), which may be incorporated with a thermoplastic elastomer preferably at 20 to 60 pts.wt. per 100 pts.wt. of the component A. The examples of the component B include a humectant, skin-whitening agent and ultraviolet ray absorbent, preferably oily (e.g. tallow, butyric acid, lauryl alcohol, liquid paraffin and carnauba wax). The coated sheet preferably has an adhesion of at least 5,000 cN/cm&lt;2&gt; , when adhered to each other.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, in particular to ophthalmology. The invention characterises application of the double extrusion method to manufacture biodegraded implants fit for implantation in orbital so that at least 75% of particles of an active agent have diametre less than 10 or 20 micron, and a method of treating the pathological eye condition with used the produced biodegraded implant. The implants are made of mixed &#34;£ôÜ&#34; with hydrophilic and hydrophobic ends. ^ EFFECT: invention provides delivery of the active agents into the orbital area without sharp emission release. ^ 15 cl, 10 tbl, 17 dwg, 8 ex